Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02595242 | Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma | Phase 1 | withdrawn | Nov 3, 2015 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | not stated | Not stated |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory…(S-BR) | Phase 2 | withdrawn | Dec 8, 2015 | University of Arizona | Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study… | Enrollment / accrual |
| NCT00082017 | UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | Phase 2 | terminated | Apr 28, 2004 | National Cancer Institute (NCI) | IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND. | Enrollment / accrual |
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary… | Phase 4 | terminated | Jun 21, 2012 | Vanderbilt University Medical Center | Difficulty recruiting. | Enrollment / accrual |
| NCT01282476 | Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | Phase 2 | terminated | Jan 25, 2011 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT01610999 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell… | Phase 1 | terminated | Jun 4, 2012 | Tufts Medical Center | Unavailability of study article | Other (stated, no rule matched) |
| NCT01889797 | Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden…(PrE0401) | Phase 2 | terminated | Jun 28, 2013 | PrECOG, LLC. | Closed due prolonged enrollment timelines | Enrollment / accrual |
| NCT00681044 | HD Melphalan and SCT in Patients With IGDD or LCDD | Phase 2 | terminated | May 20, 2008 | Boston Medical Center | Poor accrual | Enrollment / accrual |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib,… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2016 | H. Lee Moffitt Cancer Center and Research Institute | study drug unavailable | Other (stated, no rule matched) |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | Phase 2 | terminated | May 4, 2005 | SWOG Cancer Research Network | poor accrual | Enrollment / accrual |
| NCT00710151 | Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International… | — | terminated | Jul 4, 2008 | OHSU Knight Cancer Institute | not stated | Not stated |
| NCT01750762 | Lenalidomide After Allo Transplant | Phase 1 | terminated | Dec 17, 2012 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT00645359 | Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large…(dMRI) | — | terminated | Mar 27, 2008 | University of Michigan Rogel Cancer Center | Insufficient resources to evaluate pilot, second to shift in research priorities | Other (stated, no rule matched) |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | Phase 2 | terminated | Aug 2, 2010 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte… | Phase 2 | terminated | Aug 7, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma… | Phase 2 | terminated | Feb 16, 2012 | Barbara Ann Karmanos Cancer Institute | Data was not collected, because funding was unavailable to continue study. | Funding |
| NCT02285244 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | withdrawn | Nov 6, 2014 | James Blachly | Decision made by the Principal Investigator | Investigator |
| NCT02257684 | A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as… | Phase 2 | terminated | Oct 6, 2014 | Jazz Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT00490490 | Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy | Phase 2 | terminated | Jun 22, 2007 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell… | Phase 2 | terminated | Sep 23, 2010 | Tufts Medical Center | changes in practice | Other (stated, no rule matched) |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | Phase 2 | terminated | Dec 2, 2011 | Dana-Farber Cancer Institute | Low accrual. | Enrollment / accrual |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple… | Phase 1 | terminated | Nov 19, 2007 | Bristol-Myers Squibb | not stated | Not stated |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT02473523 | Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma… | N/A | terminated | Jun 16, 2015 | St. Jude Children's Research Hospital | The principal investigator left the institution. | Investigator |
| NCT01878708 | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell… | Early Phase 1 | terminated | Jun 17, 2013 | Dana-Farber Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT01954784 | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With… | Phase 1 | terminated | Oct 7, 2013 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or… | Phase 2 | terminated | Oct 2, 2014 | SCRI Development Innovations, LLC | Safety lead-in data did not support continuation of study. | Safety / toxicity |
| NCT02402725 | A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma(UltraDex) | Phase 2 | withdrawn | Mar 30, 2015 | Boston Medical Center | poor accrual | Enrollment / accrual |
| NCT01504490 | Phase I Study of CS-7017 and Bexarotene | Phase 1 | terminated | Jan 5, 2012 | Georgetown University | Drug no longer available | Other (stated, no rule matched) |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous… | Phase 2 | terminated | Apr 14, 2014 | SCRI Development Innovations, LLC | Closed early due to slow accrual. | Enrollment / accrual |
| NCT01389076 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated,… | Phase 2 | terminated | Jul 7, 2011 | University of Michigan Rogel Cancer Center | Bexxar isn't being produced by the manufacturer as of Feb. 2014 | Drug supply |
| NCT02417129 | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular… | Phase 3 | terminated | Apr 15, 2015 | Boehringer Ingelheim | not stated | Not stated |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | Phase 2 | terminated | Jan 12, 2004 | Boston Medical Center | poor accrual | Enrollment / accrual |
| NCT02578121 | UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | Phase 2 | withdrawn | Oct 16, 2015 | University of Arkansas | Investigator decided to close study without enrollment | Investigator |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients…(MM) | Phase 4 | withdrawn | Aug 5, 2011 | DFINE Inc. | not stated | Not stated |
| NCT01841021 | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma… | N/A | terminated | Apr 26, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual, loss of sponsor support | Enrollment / accrual |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV… | Phase 2 | terminated | Sep 27, 2012 | Oncotherapeutics | Terminated by Sponsor of this study. | Other (stated, no rule matched) |
| NCT01032148 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin… | Phase 1 | terminated | Dec 15, 2009 | Roswell Park Cancer Institute | lack of funding | Funding |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | Phase 2 | terminated | Jul 10, 2012 | Adam Lerner | Poor enrollment | Enrollment / accrual |
| NCT01947309 | Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) | — | terminated | Sep 20, 2013 | Celgene | Business Decision | Sponsor / business decision |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in… | Phase 2 | terminated | May 8, 2015 | Dana-Farber Cancer Institute | Safety issues from trials in CLL | Safety / toxicity |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | Phase 4 | withdrawn | Jul 1, 2015 | Jun Zhu | not stated | Not stated |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT01812720 | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously…(CARAMEL 2) | Phase 2 | withdrawn | Mar 18, 2013 | Mayo Clinic | not stated | Not stated |
| NCT01555853 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | Phase 1 | terminated | Mar 16, 2012 | Washington University School of Medicine | completed accrual to phase I but drug did not show activity, so halted before initiation of phase II | Enrollment / accrual |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With… | Phase 1 / Phase 2 | withdrawn | Sep 27, 2005 | Stanford University | not stated | Not stated |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | Phase 1 | withdrawn | May 2, 2016 | Anne Beaven, MD | Boehringer Ingelheim is discontinuing their volasertib development program | Other (stated, no rule matched) |
| NCT00978432 | Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Sep 17, 2009 | Anne Beaven, MD | The toxicity seemed to outweigh the benefit. | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 23, 2017source: clinicaltrials